These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35653982)

  • 1. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
    Nader-Marta G; Martins-Branco D; Agostinetto E; Bruzzone M; Ceppi M; Danielli L; Lambertini M; Kotecki N; Awada A; de Azambuja E
    ESMO Open; 2022 Jun; 7(3):100501. PubMed ID: 35653982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
    Yu Y; Huang K; Lin Y; Zhang J; Song C
    Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
    Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
    Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
    Yuan Y; Liu X; Cai Y; Li W
    PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
    Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
    Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
    Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
    Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Le Du F; Diéras V; Curigliano G
    Eur J Cancer; 2021 Sep; 154():175-189. PubMed ID: 34280871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
    Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
    Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis.
    Hu H; Xu ZY; Zhu Q; Liu X; Jiang SC; Zheng JH
    Front Immunol; 2021; 12():669398. PubMed ID: 34335570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
    Ouyang DJ; Chen QT; Anwar M; Xie N; Ouyang QC; Fan PZ; Qian LY; Chen GN; Zhou EX; Guo L; Gu XW; Ding BN; Yang XH; Liu LP; Deng C; Xiao Z; Li J; Wang YQ; Zeng S; Wang S; Yi W
    Front Pharmacol; 2021; 12():682568. PubMed ID: 34512325
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
    Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
    Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis.
    Werter IM; Remmelzwaal S; Burchell GL; de Gruijl TD; Konings IR; van der Vliet HJ; Menke-van der Houven van Oordt CW
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
    Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
    J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.